Cardiac Toxicity on NSABP B-31
Cardiac Toxicity on NSABP B-31
B-31 Cardiac Monitoring Program Development Group
B-31 Cardiac Monitoring Program Data Management
NSABP B-31
B-31 Design Assumptions
B-31 Cardiac Eligibility Criteria
B-31 LVEF Evaluation Schedule
NSABP B-31 - Criteria for Trastuzumab Initiation
B-31 Cardiac Event Primary Endpoint for Cardiac Safety
Symptomatic Patients Real Time Blinded Evaluation
NSABP B-31 - Cardiac Event Rates
Trastuzumab Associated CHF Risk Factors
Recovery of Patients Reporting Symptoms of Possible CHF
Histograms of Left Ventricular Ejection Fraction
B-31 LVEF Evaluation Schedule
Asymptomatic Patients Criteria for Continuing Trastuzumab
NSABP B-31 Trastuzumab Discontinuation Due to Asymptomatic or Symptomatic Cardiac Dysfunction by Quarter
Charles E Geyer Jr, MD